News in Brief
Bendy X-rays and DMT infusions: News from Imperial
Here’s a batch of fresh news and announcements from across Imperial.
Bendy X-rays and DMT infusions: News from Imperial
Here’s a batch of fresh news and announcements from across Imperial.
River sampling study shows impact of COVID-19 pandemic on London’s waterways
The most detailed study of a city’s waterways anywhere in the world has revealed how chemical pollutants in London’s rivers changed over the pandemic.
£1.5m ‘Quest for Cures’ grant to tackle aggressive brain tumours
An Imperial team engineering new techniques in cancer immunotherapy has been awarded £1.5m over five years.
New centre established to help develop drug delivery and vaccine technologies
The Intracellular Drug Delivery Centre aims to develop new drug delivery technologies and support promising RNA vaccines and therapeutics.
Imperial addiction researcher appointed to national role to tackle drug harms
Anne Lingford-Hughes has been appointed to a national role aimed at tackling addiction and improving treatment outcomes.
New partnership will use molecular glues to tackle ‘undruggable’ disease targets
Researchers at Imperial, the Francis Crick Institute and AstraZeneca will advance the discovery of new ‘molecular glues’ to treat a range of diseases.
Advanced brain imaging study hints at how DMT alters perception of reality
Scientists have gleaned new insights into how psychedelics alter conscious experience via their action on brain activity.
Wearable tech, AI and clinical teams join to change the face of trial monitoring
A multi-disciplinary team of researchers has developed a way to monitor the progression of movement disorders using motion capture technology and AI.
Imperial partnering with EnteroBiotix to advance microbiome medical treatments
Imperial is partnering with biotechnology company EnteroBiotix on research into the potential of therapies based on the gut bacterial community.
Sustainable way to make breast cancer drug could boost South African production
Imperial researchers have devised a cheaper, more efficient, and sustainable way to produce a breast cancer drug in South Africa.